PuSH - Publikationsserver des Helmholtz Zentrums München

Seufert, J.* ; Wiesli, P.* ; Fritsche, A. ; Anderten, H.* ; Pegelow, K.* ; Pscherer, S.* ; Pfohl, M.*

Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety.

Diabetes Obes. Metab., DOI: 10.1111/dom.14549 (2021)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
AIMS: This study evaluated effectiveness and safety of switching the basal insulin (BI) in a BI supported oral therapy (BOT) to insulin glargine 300 U/mL (Gla-300) in adult people with inadequately controlled type 2 diabetes (T2D). MATERIALS AND METHODS: This non-interventional, multicentre, prospective 12-month study, conducted in Germany, Austria and Switzerland, documented people with T2D with an HbA1c between 7.5-10.0%, currently treated by a non-Gla-300 BOT regimen, after the physician had decided to switch the BI to Gla-300. Primary endpoint was the proportion of patients achieving fasting plasma glucose (FPG; ≤110 mg/dL) target. RESULTS: 1,194 participants comprised the full analysis set, of which 793 completed documentation of 12 months Gla-300 treatment (FAS-M12). Main previous BI was insulin glargine 100 U/mL (Gla-100; 47.2%). Twelve months after switching to Gla-300, 27.0% of FAS-M12 participants achieved the FPG target and 44.8% their individualized HbA1c target. Greatest FPG target achievements were seen in previous Gla-100 (29.3%), and greatest HbA1c target achievements in previous insulin detemir users (57.7%). Mean FPG decreased by -36.3±51.2 mg/dL to 135.5±36.9 mg/dL and mean HbA1c by -0.79±1.01% to 7.45±0.94%. Symptomatic and nocturnal hypoglycaemia incidence significantly decreased over 12 months of Gla-300 treatment. Body weight remained unchanged. CONCLUSIONS: Switching the BI to Gla-300 in a BOT regimen improved metabolic control and treatment satisfaction in a substantial proportion of patients with T2D and inadequate target achievement within 12 months in clinical practice with decreased risk of symptomatic and nocturnal hypoglycaemia and without weight gain.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Basal Insulin ; Hypoglycaemia ; Insulin Analogues ; Insulin Therapy ; Observational Study ; Type 2 Diabetes; Hypoglycemia; Units/ml; Outcomes
ISSN (print) / ISBN 1462-8902
e-ISSN 1463-1326
Zeitschrift Diabetes, Obesity and Metabolism
Verlag Wiley
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes Research and Metabolic Diseases (IDM)
Förderungen Sanofi-Aventis Deutschland GmbH, Berlin, Germany